Safety and Efficacy During Long‐Term Treatment with Moclobemide

@article{Moll1994SafetyAE,
  title={Safety and Efficacy During Long‐Term Treatment with Moclobemide},
  author={E. Moll and N Neumann and W. Schmid-burgk and Max Stabl and R. Amrein},
  journal={Clinical Neuropharmacology},
  year={1994},
  volume={17},
  pages={S74–S87}
}
Summary: Safety aspects [adverse events, blood pressure and heart rate, weight, and laboratory tests (liver parameters, hemoglobin, leukocytes)] of long‐term treatment in 1,120 patients are discussed. Adverse events during this long‐term treatment were also compared with those of a subgroup of these patients who, before long‐term treatment, were treated on a short‐term basis (n = 706). Efficacy [Hamilton Depression Rating Scale (HAM‐D), Clinical Global Impression of Efficacy (CGI), and… Expand
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects
TLDR
The maximum tolerated dose of moclobemide in healthy subjects is 600”mg b.i.d. provided the tyramine content in a meal is not higher than 50 mg, and the incidence and intensity of adverse events was dose-dependent. Expand
Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview
TLDR
Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients and of similar efficacy to the TCAs and the more recently introduced SSRIs. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Treatment of Depression in Parkinson's with Moclobemide: A Pilot Open-label
TLDR
Though these preliminary results need to be replicated in a large controlled trial, it is suggested that moclobemide may be an effective alternative in the treatment of PD associated depression. Expand
Treatment of depression in Parkinson's disease with moclobemide: A pilot open-label study.
TLDR
Though these preliminary results need to be replicated in a large controlled trial, it is suggested that moclobemide may be an effective alternative in the treatment of PD associated depression. Expand
Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
TLDR
The combined use of moclobemide and high doses of sympathomimetic drugs should be approached with caution because of the incidence of adverse events elicited by ephedrine, particularly palpitations and headache. Expand
Pharmacokinetic dose‐proportionality study at steady state of mirtazapine from Remeron® tablets
Steady‐state dose proportionality of mirtazapine, the active constituent of Remeron® tablets, a new antidepressant developed under the laboratory code Org 3770, was investigated. Each of 27 youngExpand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
TLDR
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
Antidepressants and body weight: a comprehensive review and meta-analysis.
TLDR
This is the first comprehensive meta-analysis to allow comparison of different antidepressants as regards their impact on body weight and Quantitative results evidenced that amitriptyline, mirtazapine, and paroxetine were associated with a greater risk of weight gain. Expand
Drug Treatment of Depression in the 1990s
TLDR
The most important progress in the past 10 years has been the development of compounds which possess markedly reduced binding capacities at receptor sites not linked to their antidepressive actions. Expand
...
1
2
3
...